News summaryThe Motley FoolOct 29, 2026, 06:57 PM
Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
Bristol Myers Squibb's Growth Portfolio revenue grew 12% to $7.7 billion in the third quarter. [[fact:fact-3nj3q7a7d]] Total revenue was $13.1 billion, up 7% from the prior-year quarter. [[fact:fact-ra3p4crmq]] Earnings per share were $1.05 GAAP and $1.35 adjusted; adjusted EPS fell 17% from $1.63. [[fact:fact-x0t0r1tft]] The company raised its 2026 revenue guidance to $49.75 billion to $50.25 billion. [[fact:fact-eq7uvypvj]]